Transforming ALL Treatment: Advances and Challenges in CAR T-Cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy represents a groundbreaking approach in immunotherapy, enabling the reprogramming of a patient’s own T cells to target and destroy cancer cells directly by recognizing specific antigens, independent of traditional MHC pathways. This is particularly crucial in the context of Acute Lymphoblastic Leukemia (ALL), a rapidly progressing malignancy often complicated by relapses and issues such as graft-versus-host disease. This paper evaluates the progress, clinical effectiveness, and ongoing challenges associated with CAR T-cell therapy in treating ALL, with an emphasis on patient outcomes and future developments.

کلیدواژه ها:

Acute lymphoblastic leukemia ، ALL ، CAR T-cell ، Relapsed ، Refractory